Formulation development and characterization of piroxicam fast dissolving tablets approved for the treatment of arthritis

Piroxicam has been the most widely used potent non steroidal anti inflammatory drug used in treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gout disease for many decades. Since no systematic studies on design and development of Piroxicam FDT are available in literature, we propose to develop a suitable formulation to characterize fast dissolving tablet of Piroxicam. The aim of present study was to formulate various formulations of immediate release tablets of Piroxicam using different excipients by direct compression. The dispersible drug delivery system was developed using Croscarmellose Sodium, Sodium Starch Glycolate and Crospovidine as disintegrating agents. In the present work, formulations of Orodispersible tablets of Piroxicam were prepared using three superdisintegrants namely Crospovidone, Croscarmellose Sodium and Sodium Starch Glycolate in different concentrations (3%, 4%, 5% and 6%). The final blend and tablets of Piroxicam were evaluated for powder flow properties, bulk density, tapped density, compressibility index and hausner’s ratio, weight variation, thickness, hardness, friability, wetting time, water absorption ratio, drug content, disintegration time and in-vitro release study. Formulation F8 showed the lowest disintegration time and more water absorption ratio. In-vitro dissolution studies revealed that formulation F8 showed 96.11% percent drug release at the end of 30 minutes. Accelerated stability studies conducted for three month at 40°C and 75% RH and were found within specification.